in the stomach and the specific CCK-A receptor antagonist L-364,718 inhibited the agonist activity of 450 in the pancreas. It is concluded that the agonist effect of PD-136,450 is mediated via interaction with the gastrin (CCK-B) receptor in the stomach and the CCK-A receptor in the pancreas.
Considerable progress has been made in elucidating the physiological and pathological roles of gastrin in recent years. This has been aided by the discovery of non-peptide antagonists of gastrin (cholecystokinin type B (CCK-B)) receptors, by molecular cloning of the gastrin receptor itself, and by identification of receptors for gastrin on enterochromaffin-like (ECL) cells from mastomys gastric tumours. '-'°Receptor antagonists have a potential use in peptic ulcer disease and as adjuvant therapy in gastrin receptor positive gastrointestinal tumours, since they not only antagonise acid secretion but also inhibit the trophic effect of gastrin on For acid secretion studies, a flexible orogastric tube was introduced into the proximal portion of the stomach. A multi-orifice polyethylene tube was then inserted into the antrum through an incision in the duodenum and was brought to the exterior through the flank. The stomach was perfused with saline via the orogastric tube at 7 ml/min and effluent was collected over 10 minute intervals from the pyloric outlet. Samples were titrated with 0.1 M NaOH to an end point of pH 7-4. Basal -acid output was recorded for 30 minutes, then secretion was stimulated by intravenous injection of 1 rig/kg SHG-17. This control response was followed one hour later by subcutaneous injection of either vehicle or PD-136,450 (0-1-1-0 mg/kg). After a further 10 The significance of differences was determined by unpaired t test. Probability values of p<0-05 were regarded as significant. (Fig 2A) . PD-136,450 displayed a partial agonist action in as much as acid output in basal secreting conscious rats increased to 30 (5)% of the maximal response to gastrin itself. Dose-response studies of the stimulation of acid secretion by PD-136,450 in conscious animals showed a maximal response at 5 6 [tmol (4) (5) mg)/kg (Fig 2B) . Gastrin-17 displayed greater efficacy and was about 350 fold more potent on a molar basis. The agonist and antagonist activities decreased with time, although the duration of action of PD-136,450 was fairly lengthy after subcutaneous dosing (Fig 3) . Pretreatment with PD-136,450 did not change the basal plasma gastrin value and did not modify the pharmacokinetics of injected gastrin (Fig 4) . As shown in Figure 5 were injected subcutaneously andfive minutes later, 4 5 mglkg PD-136,450 were also injected subcutaneously. .seems to be direct in as much as PD-136,450 is known to be effective in an isolated gland preparation and does not release CCK in vivo. '7 In conclusion, PD-136,450 seems to be capable of exerting effects through both CCK-A and CCK-B recepters in vivo. It antagonises gastrin induced acid secretion, but exerts a partial agonist effect in the stomach. In the pancreas, PD-136,450 behaves as a powerful stimulant offluid secretion via a CCK-A receptor mechanism. Studies of the binding, distribution, and metabolism ofPD-136,450 in the rat in vitro and in vivo are necessary to clarify apparent discrepancies between the in vitro binding data and pharmacodynamic behaviour of the compound in vivo. Although PD-136,450 was designed for optimal activity at CCK-B receptors, further structural modification seems necessary in order to achieve selectivity of action in this series of compounds in vivo. 
